Seaport Therapeutics, Inc. stock analysis
Seaport Therapeutics, Inc. (SPTX) Stock Price & Analysis
SPTX Stock Chart & Stats
- Day’s Range
- $19.77 - $21.75
- 52-Week Range
- $14.85 - $28.38
- Previous Close
- $20.39
- Volume
- N/A
- Average Volume (3M)
- 250.78K
- Market Cap
- $1.15B
- Enterprise Value
- $793.96M
- Total Cash (Recent Filing)
- $290.43M
- Total Debt (Recent Filing)
- $4.69M
- Price to Earnings (P/E)
- ―
- Beta
- -0.03
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Seaport Therapeutics, Inc. News
Seaport Therapeutics presents additional PK data from Phase 1 GlyphAgo trial
Seaport Therapeutics (SPTX) announced the presentation of Phase 1 clinical data for GlyphAgo at the 39th European College of Neuropsychopharmacology Congress, taking place October 10-13, 2026, in Munich, Germany. The
Seaport Therapeutics announces Phase 1 Trial of GlyphAllo met primary endpoint
Seaport Therapeutics (SPTX) announced positive topline results from the Phase 1 Driving Simulation Trial of GlyphAllo, a novel, Glyphed oral prodrug of allopregnanolone, in healthy volunteers. The trial evaluated the
Selvaraju Reiterates Buy on Seaport, Citing Differentiated Neuropsychiatry Pipeline and Unchanged $50 Price Target
Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Seaport Therapeutics, Inc., retaining the price target of $50.00. Ram Selvaraju has given his Buy rating due to a
SPTX FAQ
What was Seaport Therapeutics, Inc.’s price range in the past 12 months?
What is Seaport Therapeutics, Inc.’s market cap?
When is Seaport Therapeutics, Inc.’s upcoming earnings report date?
How were Seaport Therapeutics, Inc.’s earnings last quarter?
Is Seaport Therapeutics, Inc. overvalued?
Does Seaport Therapeutics, Inc. pay dividends?
What is Seaport Therapeutics, Inc.’s EPS estimate?
How many shares outstanding does Seaport Therapeutics, Inc. have?
What happened to Seaport Therapeutics, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Seaport Therapeutics, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Seaport Therapeutics, Inc. Stock Smart Score
Company Description
Seaport Therapeutics, Inc.
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Daphne Zohar
- Employees
- 58
- Website
- www.seaporttx.com
- Address
- 101 Seaport Blvd., Boston, MA, 02210-2186, US
Seaport Therapeutics, Inc. (SPTX) Earnings & Revenues
SPTX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 5 | 2 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 10 | 0 | 0 |









